According to studies in other cancers (Felder et al., 2014b; Aithal et al., 2018; Yeku et al., 2020; Yu et al., 2020), MUC16 may also be an important immunotherapy target for ESCC. This evidence concerns the gene MUC16 and esophageal squamous cell carcinoma.